Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kristine Wesley

Nurse Practitioner, Acute Care Birmingham, AL Nurse Practitioner

NPI 1336784719 CMS profile 10916920

3056 Healthy Way Ste 100, Birmingham, AL 35201

Open in the dashboard

General payments

$2,886

84 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kristine Wesley of Birmingham, AL is reported in the CMS Open Payments database as having received $2,886 across 84 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,811 28
2024 General $311 11
2023 General $435 22
2022 General $311 22
2021 General $18 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristine Wesley
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Kristine Wesley were reported at $1,811. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Kristine Wesley Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $18 $123 $38–$327 $132
2022 $311 $130 $44–$369 $149
2023 $435 $144 $49–$410 $160
2024 $311 $146 $48–$433 $164
2025 $1,811 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abiomed $1,336 10 payments
  2. Medtronic, Inc. $541 23 payments
  3. Baxter Healthcare $220 10 payments
  4. Silk Road Medical, Inc. $168 9 payments
  5. Atricure, Inc. $116 6 payments
  6. W. L. Gore & Associates, Inc. $83 4 payments
  7. Aziyo Biologics, Inc. $67 3 payments
  8. Octapharma USA, Inc. $66 3 payments
  9. Chiesi USA, Inc. $58 3 payments
  10. CryoLife, Inc. $38 2 payments
  11. Other $193 11 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,915 80 payments
  2. Travel and Lodging $971 4 payments
Products named General payments · program years 2021–2025
  1. Valiant Navion $176 3 payments
  2. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $168 9 payments
  3. ENROUTE Transcarotid Stent $168 9 payments
  4. Avalus $153 7 payments
  5. SYNERGY ABLATION SYSTEM $116 6 payments
  6. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $114 6 payments
  7. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $114 6 payments
  8. ENDURANT IIS $83 5 payments
  9. ECM Patch,Pouch $67 3 payments
  10. CLEVIPREX $58 3 payments
  11. Other $847 43 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

637

Median for Cardiac Surgery: 68

Drug cost

$22,524

Median for Cardiac Surgery: $445

Branded share of claims

15.4%

Median for Cardiac Surgery: 15.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 25 $18,998
Atorvastatin Calcium Generic 104 $837
Clopidogrel Clopidogrel Bisulfate Brand 73 $801
Methocarbamol Generic 75 $383
Amiodarone Hcl Generic 35 $371
Potassium Chloride Generic 78 $262
Metoprolol Tartrate Generic 71 $250
Carvedilol Generic 38 $190
Metoprolol Succinate Generic 25 $175
Amlodipine Besylate Generic 19 $128

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 411 Part D prescribers listed as Cardiac Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$2,426

Medicare's payments for the services billed

Medicare patients

19

Average age 72

Services billed

36

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Diabetes 63%
Atrial fibrillation 63%
Depression 63%
Arthritis 63%
COPD 58%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

84 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Acute Care in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record